CO2024000572A2 - Compuestos pirimidínicos para usar como inhibidores de map4k1 - Google Patents
Compuestos pirimidínicos para usar como inhibidores de map4k1Info
- Publication number
- CO2024000572A2 CO2024000572A2 CONC2024/0000572A CO2024000572A CO2024000572A2 CO 2024000572 A2 CO2024000572 A2 CO 2024000572A2 CO 2024000572 A CO2024000572 A CO 2024000572A CO 2024000572 A2 CO2024000572 A2 CO 2024000572A2
- Authority
- CO
- Colombia
- Prior art keywords
- map4k1
- compounds
- pyrimidine compounds
- inhibitors
- map4k1 inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000003230 pyrimidines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 abstract 2
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente divulgación se dirige a compuestos de fórmula (I) y sales farmacéuticamente aceptables de este, que son útiles como inhibidores de MAP4K1, procesos para su preparación, composiciones farmacéuticas que comprenden los compuestos y el uso de los compuestos o las composiciones en el tratamiento o la prevención de varias enfermedades, afecciones y/o trastornos mediados por MAP4K1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202121030204 | 2021-07-06 | ||
| PCT/IB2022/056248 WO2023281417A1 (en) | 2021-07-06 | 2022-07-06 | Pyrimidine compounds for use as map4k1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2024000572A2 true CO2024000572A2 (es) | 2024-02-05 |
Family
ID=82703212
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2024/0000572A CO2024000572A2 (es) | 2021-07-06 | 2024-01-24 | Compuestos pirimidínicos para usar como inhibidores de map4k1 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230227483A1 (es) |
| EP (1) | EP4367123A1 (es) |
| KR (1) | KR20240012538A (es) |
| CN (1) | CN117730083A (es) |
| AU (1) | AU2022305807A1 (es) |
| CA (1) | CA3223874A1 (es) |
| CO (1) | CO2024000572A2 (es) |
| IL (1) | IL309342A (es) |
| PE (1) | PE20240585A1 (es) |
| WO (1) | WO2023281417A1 (es) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3548479A1 (en) * | 2016-11-30 | 2019-10-09 | ARIAD Pharmaceuticals, Inc. | Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors |
| AU2020406824A1 (en) * | 2019-12-16 | 2022-08-11 | Korea Research Institute Of Chemical Technology | Novel pyrimidine derivative and use thereof |
-
2022
- 2022-07-06 CN CN202280048104.2A patent/CN117730083A/zh active Pending
- 2022-07-06 PE PE2023003341A patent/PE20240585A1/es unknown
- 2022-07-06 IL IL309342A patent/IL309342A/en unknown
- 2022-07-06 WO PCT/IB2022/056248 patent/WO2023281417A1/en active Application Filing
- 2022-07-06 KR KR1020237044454A patent/KR20240012538A/ko active Search and Examination
- 2022-07-06 AU AU2022305807A patent/AU2022305807A1/en active Pending
- 2022-07-06 US US17/912,729 patent/US20230227483A1/en active Pending
- 2022-07-06 CA CA3223874A patent/CA3223874A1/en active Pending
- 2022-07-06 EP EP22747756.9A patent/EP4367123A1/en active Pending
-
2024
- 2024-01-24 CO CONC2024/0000572A patent/CO2024000572A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3223874A1 (en) | 2023-01-12 |
| KR20240012538A (ko) | 2024-01-29 |
| WO2023281417A1 (en) | 2023-01-12 |
| CN117730083A (zh) | 2024-03-19 |
| IL309342A (en) | 2024-02-01 |
| PE20240585A1 (es) | 2024-03-21 |
| EP4367123A1 (en) | 2024-05-15 |
| AU2022305807A1 (en) | 2024-01-04 |
| US20230227483A1 (en) | 2023-07-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000907A1 (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 (divisional de solicitud n° 01501-2020) | |
| CO2021000537A2 (es) | Inhibidores de inflamasoma nlrp3 | |
| ECSP21080740A (es) | Inhibidores del inflamasoma nlrp3 | |
| CL2022003510A1 (es) | Inhibidores de cisteína proteasas y sus métodos de uso | |
| UY37795A (es) | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 | |
| CO2018005640A2 (es) | Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria | |
| CR11491A (es) | Derivados de tiazol usados como inhibidores de pi 3-cinasa | |
| CY1118969T1 (el) | Ενωσεις πυριμιδινο-2-αμινης και η χρηση τους ως αναστολεις των κινασων jak | |
| CL2021000844A1 (es) | Compuestos de indolinona para uso como inhibidores de map4k1 | |
| CR10356A (es) | Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3 | |
| BR112016028876A2 (pt) | composto, composição farmacêutica, método para tratar uma doença ou condição em um ser humano, kit, e, uso de um composto, um sal, isômero ou uma mistura farmaceuticamente aceitável dos mesmos. | |
| CO2019001181A2 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| UY35551A (es) | Derivados heteroarilos como inhibidores de aldosterona sintasa | |
| CO2022015054A2 (es) | [1,3]diazino[5,4-d]pirimidinas como inhibidores de her2 | |
| CO6630193A2 (es) | Inhibidores de la actividad de la proteína tirosina quinasa seleccionada | |
| CL2022002975A1 (es) | Compuestos y composiciones para inhibir la actividad de hif2-alfa y sus métodos de uso | |
| CL2023000921A1 (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead | |
| BR112023012947A2 (pt) | Inibidores de lrrk2 | |
| CO2022012884A2 (es) | Compuestos de amino pirimidina fusionados | |
| UY28993A1 (es) | Tetrahidroisoquinolinas sustituidas en calidad de inhibidores de mpm, procedimiento para su uso como medicamento.- | |
| CO2024000565A2 (es) | Inhibidores del inflamasoma nlrp3 | |
| UY30862A1 (es) | Derivados de piridopirimidina, composiciones farmacéuticas conteniéndolos, procesos de preparacioon y aplicaciones | |
| CO2024000572A2 (es) | Compuestos pirimidínicos para usar como inhibidores de map4k1 | |
| UY31812A (es) | Derivados de cinolina como inhibidores de csf-1 | |
| CL2021000282A1 (es) | Inhibidores de ckd8/19 |